Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ixekizumab in TNFi-experienced radiographic axial spondyloarthritis
2015-003937-84Phase 3Completed
- Sponsor
- Eli Lilly and Company
- Start
- Dec 2015
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of ixekizumab in ankylosing spondylitis (AS) (3 arms), sponsored by Eli Lilly and Company. Primary endpoint: ASAS40 response at Week 16. Started Dec 2015; status: completed.
02
Drugs
ixekizumab
03
Conditions
ankylosing spondylitis (AS)
Beyond the preview
Go deeper on 2015-003937-84.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-003937-84.